AcelRx Pharmaceuticals, Inc.
Profile
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The company’s non-invasive, sublingual formulation technology is designed to efficiently deliver highly lipophilic drugs with consistent pharmacokinetic profiles. In November of 2018, its lead product candidate DSUVIA™ (sufentanil sublingual tablet 30 mcg) was approved by the U.S. Food and Drug Administration. In the EU, the European Commission has granted marketing approval for DZUVEO (knows in the US as DSUVIA) for use in medically monitored settings. In addition, the company has also received approval for a patient controlled analgesia system (PCA) in the EU, known as Zalviso® (sufentanil sublingual tablet system).
-